York life sciences firm expands global reach with Korean distribution deal

The subsidiary of a York-based life sciences business has secured an exclusive distribution deal in South Korea.

OptiBiotix Health has announced that its wholly-owned subsidiary, ProBiotix Health Ltd, has entered an exclusive distribution deal with INSCOBEE INC for CholBiome in the Republic of Korea.

Based at Innovation Way in Heslington, OptiBiotix Health specialises in developing compounds designed to tackle obesity, high cholesterol, diabetes and skincare.

The agreement with Inscobee is the latest in a series of deals that ProBiotix has entered into within Asia as part of its international expansion.

Mr. Mikkel Hvid-Hansen, commercial director of ProBiotix Health, commented: “Incobee is the ideal partner in the fast moving, highly dynamic and competitive South Korean health food markets where consumers seek innovative and effective natural solutions which stand out in the market.

“We welcome Inscobee into a global team of CholBiome distributors serving medical doctors and cardiovascular specialists and directly to consumers via homeshopping, pharmacies and medical clinics.

“By entering deals on CholBiome and LP LDL in India, China, Malaysia, Singapore, Indonesia, Philippines, Taiwan, Australia, and New Zealand, ProBiotix is growing sales and developing a brand presence in these strategically important Asian growth markets.”

Mr. Seung-Hyeon Nam, director of Inscobee Plc, added: “At Inscobee, we are very pleased to introduce CholBiome products to the Korean healthcare market.

“We believe CholBiome has great potential to fill the void of safe and beneficial cardiovascular health needs in the nation and expect that it will play a big role as a flagship product of Inscobee’s healthcare business. We look forward to a long and successful partnership with ProBiotix Health.”